Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$5.4M
Program Spending
82%
of total expenses go to program services
Total Contributions
$4.6M
Total Expenses
▼$5.2M
Total Assets
$16M
Total Liabilities
▼$297.1K
Net Assets
$15.7M
Officer Compensation
→$221.4K
Other Salaries
$2.4M
Investment Income
$702.9K
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$3.6M
VA/DoD Award Count
3
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$5.7M
Awards Found
7
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| VA/DoDDepartment of Defense | SKELETAL MUSCLE HYPERTROPHY AND CARDIOMETABOLIC BENEFITS AFTER SPINAL CORD INJURY. | $1.9M | FY2015 | Sep 2015 – Sep 2020 |
| VA/DoDDepartment of Defense | EPIDEMIOLOGICAL STUDY OF MILD TRAUMATIC BRAIN INJURY SEQUELAE CAUSED BY BLAST EXPOSURE DURING OPERATIONS IRAQI FREEDOM AND ENDURING FREEDOM | $1.6M | FY2008 | Sep 2008 – Oct 2012 |
| Department of Health and Human Services | REGULATION OF CHOLESTEROL METABOLISM | $864.1K | FY2006 | Sep 2006 – Jul 2011 |
| Department of Health and Human Services | NEURAL MECHANISMS OF PREMATURE VENTRICULAR CONTRACTION-INDUCED CARDIOMYOPATHY REVEALED BY TARGETED NEUROMODULATION OF THE CARDIAC NEURAXIS - FREQUENT PREMATURE VENTRICULAR CONTRACTIONS (PVCS) CAN CAUSE PVC-INDUCED CARDIOMYOPATHY (PVC-CM), PRECIPITATE ARRHYTHMIAS, INDUCE HEART FAILURE AND INCREASE CARDIAC MORTALITY. HOWEVER, THE MECHANISMS REMAIN UNCLEAR. CURRENT THERAPIES RELY SOLELY ON PVC SUPPRESSION BUT THIS MAY NOT BE VIABLE IN MANY PATIENTS NOR SUFFICIENT TO REVERSE NEURO-CARDIAC REMODELING WHICH MAY PERSIST TO INDUCE ONGOING HARM THROUGH AUTONOMIC DYSREGULATION (SYMPATHETIC OVERLOAD AND SYMPATHETIC/PARASYMPATHETIC DYSFUNCTION). WE HYPOTHESIZE THAT PVCS INDUCE NEURAL REMODELING WHICH IS A CRITICAL MEDIATOR THAT PROMOTES CARDIAC REMODELING (PVC-CM) AND CONFERS ARRHYTHMOGENESIS VIA AUTONOMIC DYSREGULATION. NEUROMODULATION PROTECTS AGAINST NEURAL REMODELING THEREBY PREVENTS OR RESTORES PVC-CM AND SUPPRESSES ARRHYTHMIAS (CENTRAL HYPOTHESIS). THROUGH A NOVEL CHRONIC DE-AFFERENTATION MODEL OF SINO-AORTIC AFFERENT DENERVATION (SAAD), WE WILL (AIM 1) TEST THE HYPOTHESIS THAT THE AFFERENT NEURAL MECHANISM OF PVC-CM IS AN ARTERIAL BAROREFLEX “SENSORY” OVERLOAD TRIGGERED BY FREQUENT PVCS AND MEDIATED VIA SAA NERVES. SAAD DAMPENS BAROREFLEX OVERLOAD AND PROTECTS AGAINST PVC- CM. WE WILL ALSO (AIM 2) TEST THE HYPOTHESIS THAT THE EFFERENT NEURAL MECHANISM OF PVC-CM IS AN EFFERENT SYMPATHETIC OVERLOAD TRIGGERED BY PVCS, HENCE BILATERAL VS UNILATERAL EFFERENT CARDIAC SYMPATHETIC DENERVATION (CSD) INCREMENTALLY PROTECTS AGAINST PVC-CM BY PROVIDING GRADED CARDIAC SHIELDING AGAINST SYMPATHETIC OVERLOAD, THUS RE-PURPOSING A CLINICALLY APPROVED ANTI-ARRHYTHMIC TREATMENT (CSD) TO NOVEL USE OF CARDIO- PROTECTION AGAINST SYMPATHETIC OVERLOAD. AS A COUNTERPART TO SURGICAL APPROACHES, WE WILL (AIM 3) TEST THE HYPOTHESIS THAT CARVEDILOL PROTECTS AGAINST PVC-CM VIA DOWNSTREAM BETA-BLOCKADE AS WELL AS VIA NOVEL AND PLEIOTROPIC NEURO-MODULATORY EFFECTS BY REDUCING SYMPATHETIC NERVE ACTIVITY, CARDIAC ADRENERGIC OVERLOAD AND PRESERVING BAROREFLEX AND EFFERENT AUTONOMIC FUNCTION BY RESTORING INTRINSIC CARDIAC NEUROTROPHY SUPPRESSED BY PVCS. TRANSLATIONALLY, WE WILL ALSO EMPLOY THERAPEUTIC VS PRE-EMPTIVE NEUROMODULATION APPROACHES. IN-VIVO ELECTROPHYSIOLOGIC STUDIES WILL ASSESS PROTECTION FROM CARDIAC ELECTRICAL REMODELING AND ARRHYTHMOGENESIS WHILE SERIAL ECHOCARDIOGRAPHY WILL ASSESS IMPACT ON CARDIAC STRUCTURAL REMODELING. NOVEL CHRONIC AMBULATORY CARDIO- NEURAL-BP TELEMETRY CAN ASSESS NEURAL REMODELING ACROSS 4 DIFFERENT NEURAL SITES CORRELATING WITH BP, HEART RATE VARIABILITY AND SPONTANEOUS ARRHYTHMOGENESIS. NOVEL PROVOCATIVE “DUAL STRESSOR” PVC AND VASOPRESSOR CHALLENGE WILL ASSESS THE NOVEL CONTRIBUTION OF DYNAMIC BAROREFLEXES TO PVC-CM, WHILE “DUAL STRESSOR” EXERCISE AND PVC CHALLENGE WILL PROTECTION AGAINST EFFERENT SYMPATHETIC AND PARASYMPATHETIC DYSFUNCTION. CELLULAR- MOLECULAR AND IN-VITRO STUDIES WILL ASSESS THE IMPACT ON INTRINSIC VS EXTRINSIC NEURAL REMODELING AND INTRACELLULAR CALCIUM REMODELING. THIS STUDY WILL PROVIDE NOVEL PROOF-OF-CONCEPT THAT AUTONOMIC REMODELING/DYSREGULATION CAUSES PVC-CM AND PRO-ARRHYTHMIA, MAP CRITICAL NEURAL SIGNALING PATHWAYS (AFFERENT, EFFERENT, DOWNSTREAM) IN THE PVC-NEURAL LOOP THUS IDENTIFY NOVEL THERAPEUTIC TARGETS AS ALTERNATIVE THERAPIES TO PVC SUPPRESSION. | $472.5K | FY2025 | Sep 2025 – May 2030 |
| Department of Health and Human Services | PROSPECTIVE ASSESSMENT OF PREMATURE VENTRICULAR CONTRACTIONS SUPPRESSION IN CARDIOMYOPATHY(PAPS): A PILOT STUDY | $406.5K | FY2017 | Aug 2017 – Jul 2021 |
| National Aeronautics and Space Administration | 21-21FLAG_2-0003 MAGNETIC RESONANCE IMAGING (MRI) TO ASSESS CHANGES TO TRABECULAR MICROARCHITECTURE OF THE HIP | $366K | FY2023 | Dec 2022 – Nov 2026 |
| VA/DoDDepartment of Defense | MTHFR FUNCTIONAL POLYMORPHISM C677T AND GENOMIC INSTABILITY IN THE ETIOLOGY OF IDIOPATHIC AUTISM IN SIMPLEX FAMILIES | $92.4K | FY2012 | Aug 2012 – Jul 2015 |
Department of Defense
$1.9M
SKELETAL MUSCLE HYPERTROPHY AND CARDIOMETABOLIC BENEFITS AFTER SPINAL CORD INJURY.
Department of Defense
$1.6M
EPIDEMIOLOGICAL STUDY OF MILD TRAUMATIC BRAIN INJURY SEQUELAE CAUSED BY BLAST EXPOSURE DURING OPERATIONS IRAQI FREEDOM AND ENDURING FREEDOM
Department of Health and Human Services
$864.1K
REGULATION OF CHOLESTEROL METABOLISM
Department of Health and Human Services
$472.5K
NEURAL MECHANISMS OF PREMATURE VENTRICULAR CONTRACTION-INDUCED CARDIOMYOPATHY REVEALED BY TARGETED NEUROMODULATION OF THE CARDIAC NEURAXIS - FREQUENT PREMATURE VENTRICULAR CONTRACTIONS (PVCS) CAN CAUSE PVC-INDUCED CARDIOMYOPATHY (PVC-CM), PRECIPITATE ARRHYTHMIAS, INDUCE HEART FAILURE AND INCREASE CARDIAC MORTALITY. HOWEVER, THE MECHANISMS REMAIN UNCLEAR. CURRENT THERAPIES RELY SOLELY ON PVC SUPPRESSION BUT THIS MAY NOT BE VIABLE IN MANY PATIENTS NOR SUFFICIENT TO REVERSE NEURO-CARDIAC REMODELING WHICH MAY PERSIST TO INDUCE ONGOING HARM THROUGH AUTONOMIC DYSREGULATION (SYMPATHETIC OVERLOAD AND SYMPATHETIC/PARASYMPATHETIC DYSFUNCTION). WE HYPOTHESIZE THAT PVCS INDUCE NEURAL REMODELING WHICH IS A CRITICAL MEDIATOR THAT PROMOTES CARDIAC REMODELING (PVC-CM) AND CONFERS ARRHYTHMOGENESIS VIA AUTONOMIC DYSREGULATION. NEUROMODULATION PROTECTS AGAINST NEURAL REMODELING THEREBY PREVENTS OR RESTORES PVC-CM AND SUPPRESSES ARRHYTHMIAS (CENTRAL HYPOTHESIS). THROUGH A NOVEL CHRONIC DE-AFFERENTATION MODEL OF SINO-AORTIC AFFERENT DENERVATION (SAAD), WE WILL (AIM 1) TEST THE HYPOTHESIS THAT THE AFFERENT NEURAL MECHANISM OF PVC-CM IS AN ARTERIAL BAROREFLEX “SENSORY” OVERLOAD TRIGGERED BY FREQUENT PVCS AND MEDIATED VIA SAA NERVES. SAAD DAMPENS BAROREFLEX OVERLOAD AND PROTECTS AGAINST PVC- CM. WE WILL ALSO (AIM 2) TEST THE HYPOTHESIS THAT THE EFFERENT NEURAL MECHANISM OF PVC-CM IS AN EFFERENT SYMPATHETIC OVERLOAD TRIGGERED BY PVCS, HENCE BILATERAL VS UNILATERAL EFFERENT CARDIAC SYMPATHETIC DENERVATION (CSD) INCREMENTALLY PROTECTS AGAINST PVC-CM BY PROVIDING GRADED CARDIAC SHIELDING AGAINST SYMPATHETIC OVERLOAD, THUS RE-PURPOSING A CLINICALLY APPROVED ANTI-ARRHYTHMIC TREATMENT (CSD) TO NOVEL USE OF CARDIO- PROTECTION AGAINST SYMPATHETIC OVERLOAD. AS A COUNTERPART TO SURGICAL APPROACHES, WE WILL (AIM 3) TEST THE HYPOTHESIS THAT CARVEDILOL PROTECTS AGAINST PVC-CM VIA DOWNSTREAM BETA-BLOCKADE AS WELL AS VIA NOVEL AND PLEIOTROPIC NEURO-MODULATORY EFFECTS BY REDUCING SYMPATHETIC NERVE ACTIVITY, CARDIAC ADRENERGIC OVERLOAD AND PRESERVING BAROREFLEX AND EFFERENT AUTONOMIC FUNCTION BY RESTORING INTRINSIC CARDIAC NEUROTROPHY SUPPRESSED BY PVCS. TRANSLATIONALLY, WE WILL ALSO EMPLOY THERAPEUTIC VS PRE-EMPTIVE NEUROMODULATION APPROACHES. IN-VIVO ELECTROPHYSIOLOGIC STUDIES WILL ASSESS PROTECTION FROM CARDIAC ELECTRICAL REMODELING AND ARRHYTHMOGENESIS WHILE SERIAL ECHOCARDIOGRAPHY WILL ASSESS IMPACT ON CARDIAC STRUCTURAL REMODELING. NOVEL CHRONIC AMBULATORY CARDIO- NEURAL-BP TELEMETRY CAN ASSESS NEURAL REMODELING ACROSS 4 DIFFERENT NEURAL SITES CORRELATING WITH BP, HEART RATE VARIABILITY AND SPONTANEOUS ARRHYTHMOGENESIS. NOVEL PROVOCATIVE “DUAL STRESSOR” PVC AND VASOPRESSOR CHALLENGE WILL ASSESS THE NOVEL CONTRIBUTION OF DYNAMIC BAROREFLEXES TO PVC-CM, WHILE “DUAL STRESSOR” EXERCISE AND PVC CHALLENGE WILL PROTECTION AGAINST EFFERENT SYMPATHETIC AND PARASYMPATHETIC DYSFUNCTION. CELLULAR- MOLECULAR AND IN-VITRO STUDIES WILL ASSESS THE IMPACT ON INTRINSIC VS EXTRINSIC NEURAL REMODELING AND INTRACELLULAR CALCIUM REMODELING. THIS STUDY WILL PROVIDE NOVEL PROOF-OF-CONCEPT THAT AUTONOMIC REMODELING/DYSREGULATION CAUSES PVC-CM AND PRO-ARRHYTHMIA, MAP CRITICAL NEURAL SIGNALING PATHWAYS (AFFERENT, EFFERENT, DOWNSTREAM) IN THE PVC-NEURAL LOOP THUS IDENTIFY NOVEL THERAPEUTIC TARGETS AS ALTERNATIVE THERAPIES TO PVC SUPPRESSION.
Department of Health and Human Services
$406.5K
PROSPECTIVE ASSESSMENT OF PREMATURE VENTRICULAR CONTRACTIONS SUPPRESSION IN CARDIOMYOPATHY(PAPS): A PILOT STUDY
National Aeronautics and Space Administration
$366K
21-21FLAG_2-0003 MAGNETIC RESONANCE IMAGING (MRI) TO ASSESS CHANGES TO TRABECULAR MICROARCHITECTURE OF THE HIP
Department of Defense
$92.4K
MTHFR FUNCTIONAL POLYMORPHISM C677T AND GENOMIC INSTABILITY IN THE ETIOLOGY OF IDIOPATHIC AUTISM IN SIMPLEX FAMILIES
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: SOUNK
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $5.4M | $4.6M | $5.2M | $16M | $15.7M |
| 2023 | $5.7M | $4.9M | $4.4M | $15.8M | $15.6M |
| 2022 | $5.2M | $5M | $4.4M | $14.6M | $14.3M |
| 2021 | $5.8M | $5.7M | $3.6M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Sheryl Underwood | Exec Director | 40 | $122.3K | $0 | $0 | $122.3K |
| Mikela July | Financial Officer | 40 | $99.7K | $0 | $0 | $99.7K |
| Jose Huizar | Chairman Of The Board | 3 | $0 | $0 | $0 | $0 |
Sheryl Underwood
Exec Director
$122.3K
Hrs/Wk
40
Compensation
$122.3K
Related Orgs
$0
Other
$0
Mikela July
Financial Officer
$99.7K
Hrs/Wk
40
Compensation
$99.7K
Related Orgs
$0
Other
$0
Jose Huizar
Chairman Of The Board
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Franklin Zieve | Principal Investigator | 20 | $145.4K | $0 | $0 | $145.4K |
Franklin Zieve
Principal Investigator
$145.4K
Hrs/Wk
20
Compensation
$145.4K
Related Orgs
$0
Other
$0
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Anthony J Minisi Md | Director | 3 | $0 | $0 | $0 | $0 |
| Denise Lester | Director | 3 | $0 | $0 | $0 | $0 |
| J Ronald Johnson | Director | 3 | $0 | $0 | $0 | $0 |
| Julie Beales Md | Director - Ended 08/15/2024) | 3 | $0 | $0 | $0 | $0 |
| Lenore N Joseph Md | Director | 3 | $0 | $0 | $0 | $0 |
| Mary Farrell | Director |
Anthony J Minisi Md
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Denise Lester
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
J Ronald Johnson
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
| $13.5M |
| $13.4M |
| 2020 | $5M | $4.8M | $4.1M | $11.5M | $11.2M |
| 2019 | $5.5M | $5.1M | $4.7M | $10.6M | $10.4M |
| 2018 | $6.1M | $5.8M | $4.3M | $10M | $9.8M |
| 2017 | $4.1M | $3.9M | $3.9M | $8.5M | $8.2M |
| 2016 | $2.9M | $2.7M | $3.7M | $8.1M | $8M |
| 2015 | $2.9M | $2.7M | $2.7M | $9M | $8.8M |
| 2014 | $2.5M | $2.4M | $3.2M | $8.7M | $8.7M |
| 2013 | $3.1M | $3M | $3.9M | $9.5M | $9.3M |
| 2012 | $2.7M | $2.6M | $3.2M | $9.6M | $9.6M |
| 2011 | $3.1M | $3M | $3.6M | $10.2M | $10.2M |
PDF not yet published by IRSView Filing → |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| 3 |
| $0 |
| $0 |
| $0 |
| $0 |
| Michael Godschalk Md | Director | 3 | $0 | $0 | $0 | $0 |
| Michael Pandak Md | Director | 3 | $0 | $0 | $0 | $0 |
| Thomas Murphy | Director - Interim Chief Of Staff (started 11/21/2 | 3 | $0 | $0 | $0 | $0 |
Julie Beales Md
Director - Ended 08/15/2024)
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Lenore N Joseph Md
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Mary Farrell
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Michael Godschalk Md
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Michael Pandak Md
Director
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0
Thomas Murphy
Director - Interim Chief Of Staff (started 11/21/2
$0
Hrs/Wk
3
Compensation
$0
Related Orgs
$0
Other
$0